• Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside: 137.74%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$13.46
▼ -0.18 (-1.32%)

This chart shows the closing price for MDWD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MediWound Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDWD

Analyst Price Target is $32.00
▲ +137.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MediWound in the last 3 months. The average price target is $32.00, with a high forecast of $36.00 and a low forecast of $28.00. The average price target represents a 137.74% upside from the last price of $13.46.

This chart shows the closing price for MDWD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in MediWound. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00Low
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00Low
1/16/2024HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $28.00Low
11/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$26.00Low
9/21/2023HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $26.00Low
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
8/17/2023OppenheimerLower TargetOutperform ➝ Outperform$63.00 ➝ $36.00Low
3/17/2023HC WainwrightReiterated RatingBuy$23.00Low
1/4/2023HC WainwrightBoost TargetBuy$5.50 ➝ $23.00Low
12/30/2022CowenBoost TargetOutperform$6.00 ➝ $25.00Low
12/22/2022Maxim GroupInitiated CoverageBuyLow
11/16/2022HC WainwrightLower TargetBuy$42.00 ➝ $38.50Low
8/10/2022HC WainwrightLower Target$45.50 ➝ $42.00Low
7/18/2022OppenheimerReiterated RatingOutperform$49.00Low
5/18/2022Wells Fargo & CompanyBoost TargetOverweight$56.00Low
3/21/2022AegisLower TargetBuy$63.00 ➝ $49.00Medium
8/17/2021AegisLower TargetBuy$70.00 ➝ $63.00Medium
8/11/2021HC WainwrightLower TargetBuy$49.00 ➝ $45.50High
6/10/2021OppenheimerReiterated RatingBuy$49.00High
3/2/2021AegisInitiated CoverageBuy$70.00High
2/26/2021HC WainwrightBoost TargetBuy$38.50 ➝ $49.00High
9/23/2020BTIG ResearchInitiated CoverageBuy$42.00Medium
8/7/2020HC WainwrightReiterated RatingBuyMedium
7/1/2020HC WainwrightReiterated RatingBuy$38.50High
6/30/2020OppenheimerReiterated RatingBuy$49.00Low
5/21/2020HC WainwrightReiterated RatingBuy$38.50Low
5/18/2020OppenheimerInitiated CoverageBuy$49.00High
1/7/2020HC WainwrightReiterated RatingBuy$38.50Low
11/15/2019HC WainwrightReiterated RatingBuy$38.50Medium
8/14/2019OppenheimerLower TargetOutperform$105.00 ➝ $49.00High
8/5/2019HC WainwrightInitiated CoverageBuy$38.50High
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
MediWound logo
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Read More

Today's Range

Now: $13.46
Low: $12.78
High: $13.82

50 Day Range

MA: $16.93
Low: $13.46
High: $19.27

52 Week Range

Now: $13.46
Low: $7.10
High: $19.86

Volume

199,000 shs

Average Volume

64,596 shs

Market Capitalization

$124.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of MediWound?

The following sell-side analysts have issued research reports on MediWound in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for MDWD.

What is the current price target for MediWound?

2 Wall Street analysts have set twelve-month price targets for MediWound in the last year. Their average twelve-month price target is $32.00, suggesting a possible upside of 137.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting MDWD will reach $36.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $28.00 for MediWound in the next year.
View the latest price targets for MDWD.

What is the current consensus analyst rating for MediWound?

MediWound currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDWD will outperform the market and that investors should add to their positions of MediWound.
View the latest ratings for MDWD.

What other companies compete with MediWound?

How do I contact MediWound's investor relations team?

MediWound's physical mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company's listed phone number is 972779714100 and its investor relations email address is [email protected]. The official website for MediWound is www.mediwound.com. Learn More about contacing MediWound investor relations.